Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(30)
PROCEDURE(5)
DRUG(4)
Biospecimen Collection
4 trials
phase_1phase_1_2phase_2
ohsu-knight-cancer-institute
Obinutuzumab
3 trials
phase_1phase_1_2phase_2
ohsu-knight-cancer-institute
Computed Tomography
3 trials
phase_1phase_1_2
ohsu-knight-cancer-institute
Echocardiography
3 trials
phase_1phase_1_2
ohsu-knight-cancer-institute
Ibrutinib
2 trials
phase_1_2phase_2
ohsu-knight-cancer-institute
Bone Marrow Biopsy
2 trials
phase_1phase_1_2
ohsu-knight-cancer-institute
Magnetic Resonance Imaging
2 trials
phase_1_2
ohsu-knight-cancer-institute
Mosunetuzumab
1 trial
phase_1_2
ohsu-knight-cancer-institute

+19 more interventions

27 unique interventions3 categories

Analytics

Trial Phases

Phase 13
Phase 24

Trial Status

Completed1
Recruiting4

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT06895473Phase 2Recruiting
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
Hematopoietic and Lymphatic System Neoplasm
PrincipalinvestigatorStart date: 2025-06-04
NCT06357676Phase 1/2Recruiting
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Mantle Cell Lymphoma
PrincipalinvestigatorStart date: 2025-05-29
NCT06249191Phase 1/2Recruiting
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma
PrincipalinvestigatorStart date: 2024-06-13
NCT05943496Phase 1Recruiting
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
PrincipalinvestigatorStart date: 2023-10-02
NCT02736617Phase 2Completed
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
PrincipalinvestigatorStart date: 2016-07-05

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse

Worked with same sponsors:

Genentech, Inc.Incyte Corporation
Similarity Score9%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score9%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score9%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse
Similarity Score9%

Carlos Montalbán Sanz, MD

Hospital Universitario Ramon y Cajal

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score9%

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseHigh Grade B-Cell Lymphoma
Similarity Score9%

Eulogio Conde García, MD

Hospital Marqués de Valdecilla

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score9%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse
Similarity Score9%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, Diffuse
Similarity Score9%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
Similarity Score9%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT06895473Phase 2PrincipalInvestigator

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

Hematopoietic and Lymphatic System Neoplasm
Recruiting
NCT06357676Phase 1/2PrincipalInvestigator

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Mantle Cell Lymphoma
Recruiting
NCT06249191Phase 1/2PrincipalInvestigator

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma
Recruiting
NCT05943496Phase 1PrincipalInvestigator

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia
Recruiting
NCT02736617Phase 2PrincipalInvestigator

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Completed

All 5 trials loaded